截至2025年12月31日，AC Immune SA持有的现金资源总额为9140万瑞士法郎。这一充裕的资金储备将为公司持续运营提供坚实保障，预计可支持其各项研发及商业活动直至2027年第三季度末。
凭借这笔资金，AC Immune SA在神经退行性疾病领域的关键项目将获得稳定推进。公司目前专注于阿尔茨海默症、帕金森病等疾病的精准医疗解决方案开发，充足的现金流为其长期战略实施创造了有利条件。
财务数据显示，AC Immune SA的资金状况稳健。9140万瑞郎的现金储备不仅覆盖了未来近两年的运营需求，更为公司应对市场变化、把握发展机遇提供了灵活空间。这一资金规划体现了管理层对财务风险控制的重视，也为投资者带来了信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.